OBJECTIVE： To compare clinical efficacy and safety of intravenous dripping of methotrexate and uterine arterial perfusion embolization combined with complete curettage of uterine cavity （CCUC） in the treatment of cesarean scar pregnancy （CSP）. METHODS： A total of 90 CSP patients were randomly divided into group A and B， with 45 cases in each group. Group A was given Methotrexate （MTX） injection 50 mg/m2 intravenously before CCUC. Group B received Seldinger catheterization in supine position before CCUC， and was given sequential infusion of MTX injection 50 mg/m2 and gelatin sponge particles into the uterine artery； the catheter was removed after satisfactory embolization by imaging examination. The levels of β-HCG of 2 groups were reexamined every 24 h， and CCUC was performed when serum β-HCG level was below 1 000 mU/mL. Perioperative bleeding volume， postoperative bleeding volume， the time of blood β-HCG returning to normal， the time of menstruation returning to normal， hospitalization time as well as the lesion diameters， the levels of blood β-HCG， the occurrence of compliance and ADR before and after treatment were compared between 2 groups. RESULTS： The intraoperative bleeding amount and postoperative bleeding amount of group B were significantly lower than those of group A， while the time of blood β-HCG returning to normal， the time of menstruation returning to normal and hospitalization time were significantly shorter than group A， and the incidence of total compliance was significantly lower than group A， with statistical significance （P＜0.05）. Before medication， there was no statistical significance in lesion diameters between 2 groups （P＞0.05）. Before CCUA， the lesion diameters of 2 groups were significantly smaller than before medication， and the group B was significantly smaller than group A， with statistical significance （P＜0.05）. Before medication， there was no statistical significance in blood β-HCG levels between 2 groups （P＞0.05）. Before and after CCUC， blood β-HCG levels of 2 groups were significantly lower than before medication， and the group B was significantly lower than group A， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups（P＞0.05）. CONCLUSIONS： Compared with methotrexate by intravenous drip， methotrexat by uterine artery embolization combined with CCUC for CSP can effectively reduce intraoperative bleeding amount， promote the decrease of blood β-HCG and menstrual recovery， and contribute to the reduction of complication risk with good safety.